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Background: Feline leukaemia virus (FeLV) is a pathogen causing fatal illness in cats worldwide, and as such there
is a high demand for products to protect against disease. The duration of immunity provided by an inactivated
FeLV vaccine, Versifel FeLV, when administered to cats of the target age was determined. Kittens received two
vaccinations when aged 7 to 9 weeks old, and were subsequently challenged up to 36 months later with the
FeLV-A Glasgow isolate.
Results: In all studies, all of the younger aged control kittens showed persistent FeLV p27 antigenaemia confirming
that the challenge virus was severe and efficacious. In contrast, the control cats did not show the required level of
persistent antigenaemia, with a maximum of 45% cats affected in the middle duration study and only 10% in the
longer study. However, apart from one animal in the short duration study, all of the cats vaccinated with Versifel
FeLV were negative for persistent antigenaemia and can be considered treatment successes.
Conclusion: In conclusion, we have shown that although age-related resistance to infection with a virulent FeLV
challenge is evident from as early as 10 months of age, vaccination with Versifel FeLV may aid in the protection of
cats from FeLV related disease up to three years after primary vaccination as kittens.
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Feline leukaemia virus (FeLV) is a gamma-retrovirus [1]
and a significant pathogen of domestic cats throughout
the world, and also other small felids such as the wildcat
and lynxes [2]. Contact and saliva are the main modes of
transmission although faeces have also been shown to
contain virus shed from infected cats [3]. Cats exposed to
FeLV may become either persistently viraemic or recover
from the infection, with young cats being more rapidly
infected following contact exposure [4]. A third category
of cats infected with FeLV are those with a latent infection;
they are not viraemic, but have a covert infection and do
not develop FeLV disease [5]. Viraemic animals do not re-
spond to FeLV antigens and show limited response to the* Correspondence: Stephen.wilson@pfizer.com
1Veterinary Medicine Research and Development, Pfizer Animal Health, Pfizer
European Service Centre, Zaventem, Belgium
Full list of author information is available at the end of the article
© 2012 Wilson et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orvirus, and are as a result at higher risk of developing fatal
disease. Those cats which do recover from the infection
produce virus neutralising antibodies which are consid-
ered important in preventing re-infection and can be
passed through colostrum to protect neonatal kittens [6].
Antibodies to the feline oncornavirus-associated cell
membrane antigen (FOCMA) can also be induced, which
protect against the development of FeLV-related neoplas-
tic disease [7]. In addition to antibody-mediated responses
the role of cell-mediated immune responses may also be
involved with protection.
As FeLV is still a significant pathogen of domestic cats
worldwide it is clear that there are demands for methods
to protect against infection or virus-related disease. Pre-
vious studies reviewed by Sparkes [8] have examined the
protection of cats against infection afforded by vaccin-
ation with a variety of commercial vaccines, which were
shown to vary considerably in efficacy. Another studyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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following vaccination with Leukocell™ 2 and showed
duration of immunity lasting at least 12 months follow-
ing the primary course [7]. Here we present data from
three separate clinical studies examining protection
against FeLV-related disease at 8, 20 and 36 months after
the primary vaccination regimen.Methods
Experimental design
Three separate studies were conducted; all were
established with two treatment groups (control and
vaccinates) but as a high level of age related resist-
ance to challenge has been reported [4] a third group
of young kittens was added to each study immediately
prior to challenge in order to validate the challenge
virus titre and associated regimen.
The studies utilised a randomised complete block
design, and Tables 1, 2 and 3 illustrate each study
design.
Animals were examined for the presence of FeLV p27
antigen in sera collected weekly from three weeks after
challenge to 15 week after challenge. The studies were
run at a Contract Research Organisation at the Univer-
sity of Lyon, France, and complied with both the institu-
tional operating procedures, appropriate animal welfare
legislation and separate Pfizer ethical review processes.Animals
All animals were specified pathogen free, European
mixed breed cats, 51 to 63 days of age on day 0 (groups
T01, T02, T04, T05, T07 and T08) or 72 to 109 days old
(groups T03, T06 and T09) prior to challenge, and
obtained from a commercial breeder. Cats were equally
split between males and females in all treatment groups.
Cats were routinely tested by ELISA for the presence or
absence of antibodies to the following pathogens – cali-
civirus, FIV, FeLV, infectious peritonitis, viral rhinotra-
cheitis, panleukopenia, intestinal coronavirus and
rotavirus – by a commercial diagnostic laboratory using
proprietary assays and analytical methods.
All study animals were negative for FeLV p27 antigen,
and anti-FOCMA and gp70 antibodies prior to vaccin-









T01 Water for Injection 1 mL 0, 21
T02 Versifel FeLV 1 mL 0, 21
T03 - - -Vaccine
The vaccine used was an experimental serial of Versifel
FeLV, containing inactivated feline leukaemia virus at a
minimum dose and a proprietary adjuvant system.
Challenge material
Prior to administration of the viral challenge, a sufficient
volume of the frozen FeLV-A Glasgow [9] isolate stock
(mean titre 5.78 x 106 ffu/mL) was thawed in a sterile
container. The FeLV challenge suspension for adminis-
tration to cats was prepared by a 1:10 dilution of the
stock virus to a target concentration of 5.78 x 105 ffu/mL
using sterile DMEM and HEPES buffers as diluents.
The site for the intraperitoneal injection was the cau-
dolateral aspect of the right ventral abdomen. Using a
separately prepared sterile syringe and needle for each
cat, and taking care to avoid puncturing internal organs
or the intestines, 1 mL of the FeLV challenge suspension
was injected into the caudolateral peritoneal cavity of
each animal in groups T03 to T09. Cats in groups T01
and T02 received a 2 mL dose. Cats were challenged ei-
ther 8 months, 20 months or 36 months after vaccin-
ation. Previous laboratory studies performed by the
authors indicated that this challenge titre, volume and
route of administration were sufficient to result in FeLV
infection in younger animals.
Animal observations
All study animals were observed at least once daily for
signs of distress or ill health. In addition, cats and kittens
had a physical examination prior to enrolment and vac-
cination (if applicable). Clinical observations, rectal
temperature and injection site measurements were also
performed following vaccinations and also at the time of
sample collection following challenge.
Sample collection
Blood samples (approximately 2 mL on each occasion)
were collected from the jugular vein into plain tubes
(without anti-coagulant) using disposable sterile needles.
If deemed appropriate by the investigator cats could be
sedated prior to sample collection.
Baseline blood samples were collected from each kitten
in T01 and T02 on study day -3 and T03 on day 238 prior








SC 243 2 mL/IP 11
SC 243 2 mL/IP 16
- 243 1 mL/IP 5

















T04 Water for Injection 1 mL 0, 21 SC 631 1 mL/IP 11
T05 Versifel FeLV 1 mL 0, 21 SC 631 1 mL/IP 16
T06 - - - - 631 1 mL/IP 6
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groups on a weekly basis (271, 278, 285, 292, 299, 306,
313, 320, 327, 334, 341 and 348) until study completion.
Blood samples were collected from each kitten in T04
and T05 on study days −1 and 617 and from group T06
on day 629. Three weeks after challenge, commencing
on day 652, blood samples were collected from all three
groups on a weekly basis (659, 666, 673, 680, 687, 694,
701, 708, 715, 722, 729 and 736) until study completion.
Blood samples were collected from each kitten in T07
and T08 on study days -1, 100, 982 and 1052 and from
kittens in T09 on study day 1136. Three weeks after
FeLV challenge, commencing on study day 1164, blood
samples were collected from all three groups on a
weekly basis (on study days 1164, 1171, 1178, 1185,
1192, 1199, 1206, 1213, 1220, 1227, 1234, 1241 and
1248) until study completion.
Blood samples collected from each animal were
stored overnight in a refrigerator and then centrifuged
the following day at approximately 3000 rpm for ap-
proximately 15 minutes, as per site standard operat-
ing procedures. Following centrifugation, serum was
harvested from each tube and divided into two ali-
quots, labelled and stored frozen in cryogenic tubes
at ≤ -70 °C. Blood and serum samples were collected
and individually labelled. One of the two aliquots of
serum was despatched to a Contract Research Labora-
tory and analysed for FeLV p27-antigen (PetChek
FeLV Antigen Test Kit, IDEXX) as per the test kit
instructions, with further confirmatory analysis per-
formed on highly positive samples. This assay uses
commercial proprietary technology but has a pub-
lished relative sensitivity of 98.6% and relative specifi-
city of 98.2%. The presence of gp70 antibodies was
evaluated by ELISA according to the test kit instruc-
tions (FeLV gp70 Antibody ELISA, European Veterin-
ary Laboratory) and anti-FOCMA antibodies were
evaluated by IFA according to the analytical labora-









T07 Water for Injection 1 mL 0, 21
T08 Versifel FeLV 1 mL 0, 21
T09 - - -antibody ELISA a titre greater than 90 was considered
positive while for anti-FOCMA antibodies a titre
greater than 20 was considered positive. All assays
were validated by the analytical laboratory prior to
use in these studies according to their standard oper-




The primary efficacy variable was the p27 antigen ana-
lysis of serum samples. According to the Monograph
01/2005:1321 Feline Leukaemia Vaccine (Inactivated)
only summaries of the data need be presented in terms
of the number and percentage of animals with persistent
antigenaemia (as determined by p27 protein), by treat-
ment group. Persistent antigenaemia for an animal was
defined (as per Pharmacopoeia) as being when an animal
was positive for the p27 antigen for three consecutive
weeks or on five separate occasions (consecutively or
not) from the third week to the fifteenth week after
FeLV challenge.
Secondary variables
Gp70 antibody and anti-FOCMA antibody results were
summarised by treatment group and time by calculating
the geometric means, minimums and maximums and
categorical results by test result and treatment group.
Body Weight for each day was summarised in terms of
mean, standard deviation, minimum and maximum for
each treatment group.
Rectal temperature was summarised by calculating de-
scriptive statistics including the mean, standard deviation,
minimum and maximum, by treatment group and day.
Results
Pre-treatment and pre-challenge FeLV serology status
The geometric mean titres of gp70 antibodies are listed








SC 1143 1 mL/IP 11
SC 1143 1 mL/IP 16
- 1143 1 mL/IP 6
Table 4 Geometric mean gp70 antibody titre, 20 month DOI
Day Group <30 <30 / 30 30 30 /<30 90 /<30 30 / 90 90 90 / 30 90 / 270 270 270 / 90 270 /≥810 ≥810 Geometric
mean
−1 T04 (n = 11) 11 0 0 0 0 0 0 0 0 0 0 0 0 10
T05 (n = 16) 16 0 0 0 0 0 0 0 0 0 0 0 0 10
42 T04 (n = 11) 11 0 0 0 0 0 0 0 0 0 0 0 0 10
T05 (n = 16) 6 0 2 1 0 0 4 0 0 1 0 1 1 42.3
617 T04 (n = 11) 9 0 1 0 0 0 0 0 0 1 0 1 0 14.9
T05 (n = 16) 5 1 1 0 1 1 1 2 1 0 1 1 0 36.5
629 T06 (n = 6) 6 0 0 0 0 0 0 0 0 0 0 0 0 10
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T04, T05, T07 and T08 were negative for FeLV p27
antigen, gp70 antibodies (i.e. ≤90; geometric mean =
10) and anti-FOCMA antibodies (i.e. ≤20; geometric
mean = 5; data not shown). Baseline serum samples of
the kittens in the additional T03, T06 and T09 groups
were negative for FeLV p27 antigen, gp70 antibodies
(i.e. ≤90; geometric mean = 10) and anti-FOCMA anti-
bodies (i.e. ≤20; geometric mean = 5; data not shown).
Therefore all animals fulfilled the criteria for inclu-
sion in the study as defined in the European Pharma-
copeia 5.0 Monograph 01/2005:1321 regarding Feline
Leukaemia Vaccine (inactivated).Efficacy of protection; p27 antigenaemia
The number and percentage of animals positive for the
FeLV p27 antigen at each time point together with the
total number and percentage of animals in each treat-
ment group with persistent antigenaemia are sum-
marised in Table 6 (8 month study, groups T01 – T03),
Table 7 (20 month study; groups T04 – T06) and Table 8
(36 month study; groups T07 – T09).Table 5 Geometric mean gp70 antibody titre, 36 month DOI
Day Group <30 <30 / 30 30 30 /<30 90 /<30 <30 / 90 30 /
−1 T07 (n = 11) 11 0 0 0 0 0 0
T08 (n = 16) 16 0 0 0 0 0 0
42 T07 (n = 11) 11 0 0 0 0 0 0
T08 (n = 16) 6 0 6 1 0 0 0
100 T07 (n = 11) 10 0 0 0 0 1 0
T08 (n = 15) 11 0 0 0 0 0 2
982 T07 (n = 10) 5 2 1 1 0 0 0
T08 (n = 14) 11 0 0 0 0 0 0
1052 T07 (n = 10) 3 0 2 3 0 0 1
T08 (n = 14) 10 0 0 1 0 0 0
1136 T07 (n = 10) 4 0 1 0 0 0 1
T08 (n = 14) 6 0 2 2 0 0 0
T09 (n = 6) 6 0 0 0 0 0 0Eight month challenge
In treatment group T01 (water for injection), six individ-
ual cats were seen to be positive for FeLV p27 antigen
on one or more occasions after administration of the
FeLV viral challenge on study day 243; of these six ani-
mals, four met the criteria for persistent antigenaemia.
The remaining five cats in T01 were negative for FeLV
p27 antigen throughout the period of assessment. Thus
the rate of persistent infection with FeLV in T01 was
36.4% (four out of 11 cats).
Of the 15 cats enrolled in group T02 (Versifel FeLV)
only one animal was observed to be positive for FeLV p27
antigen post-challenge; this cat was positive on each sam-
pling occasion from study day 264 to 348 (inclusive) and
therefore met the criteria for persistent antigenaemia.
Thus for group T02, where 14 out of 15 cats treated with
Versifel FeLV did not develop any signs of infection with
the FeLV virus, the treatment success rate was 93.3%.
Four out of five (80.0%) of the kittens enrolled in T03
and which had received no treatment, were observed to
be positive for FeLV p27 antigen on each post challenge
sampling occasion and therefore these four animals each
met the criteria for persistent antigenaemia.90 90 90 / 30 90 / 270 270 270 / 90 270 /≥810 ≥810 Geometric
mean
0 0 0 0 0 0 0 10
0 0 0 0 0 0 0 10
0 0 0 0 0 0 0 10
0 0 0 1 0 0 2 33.3
0 0 0 0 0 0 0 10
0 0 1 0 0 0 1 20.1
1 0 0 0 0 0 0 16.4
0 0 0 1 0 1 1 22.8
1 0 0 0 0 0 0 21.6
1 0 0 2 0 0 0 19.5
2 0 0 2 0 0 0 39.5
2 0 1 1 0 0 0 26.7
0 0 0 0 0 0 0 10
Table 6 Number and percentage if animals positive for FeLV p27 antigen, and with persistent antigenaemia,
8 month DOI
Study Day T01 (water) T02 (Versifel FeLV) T03 (no treatment)
Number of animals Number (%) Number of animals Number (%) Number of animals Number (%)
−3 11 0 (0.0) 15 0 (0.0) n/a n/a
238 11 0 (0.0) 15 0 (0.0) n/a n/a
243 n/a n/a n/a n/a 5 0 (0.0)
264 11 5 (45.5) 15 1 (6.7) 5 4 (80.0)
271 11 5 (45.5) 15 1 (6.7) 5 4 (80.0)
278 11 4 (36.4) 15 1 (6.7) 5 4 (80.0)
285 11 5 (45.5) 15 1 (6.7) 5 4 (80.0)
292 11 4 (36.4) 15 1 (6.7) 5 4 (80.0)
299 11 4 (36.4) 15 1 (6.7) 5 4 (80.0)
306 11 4 (36.4) 15 1 (6.7) 5 4 (80.0)
313 11 4 (36.4) 15 1 (6.7) 5 4 (80.0)
320 11 4 (36.4) 15 1 (6.7) 5 4 (80.0)
327 11 4 (36.4) 15 1 (6.7) 5 4 (80.0)
334 11 4 (36.4) 15 1 (6.7) 5 4 (80.0)
341 11 4 (36.4) 15 1 (6.7) 5 4 (80.0)
348 11 4 (36.4) 15 1 (6.7) 5 4 (80.0)
Number and percentage of animals with persistent antigenaemia
11 4 (36.4) 15 1 (6.7) 5 4 (80.0)
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In group T04 (water for injection), six of the 11 cats
were positive for FeLV p27 antigen on day 652, three
weeks after challenge. Of these six, three cats remained
positive for FeLV p27 antigen until the end of the study.
Of the 11 animals in this treatment group five (45.5%)
met the criteria for persistent antigenaemia.
Of the 16 cats enrolled in group T05 (Versifel FeLV)
one died before challenge and analysis of the serum
from the remaining 15 cats indicated that two were posi-
tive for FeLV p27 antigen three weeks after challenge,
but thereafter remained negative until study completion.
All other cats were negative throughout the study. Over-
all, none of the cats met the criteria for persistent anti-
genaemia and consequently all were considered
treatment successes.
All of the six kittens enrolled in group T06, which
received no treatment were positive for FeLV p27 anti-
gen on each occasion on which serum samples were col-
lected. Consequently, all six cats in this treatment group
met the criteria for persistent p27 antigenaemia.36 Month challenge
In treatment group T07 (water for injection) one cat was
euthanased on study day 213suffering from dyskinesia
and of the ten cats remaining one was positive for FeLV
p27 antigen on study day 1164, three weeks after chal-
lenge, and remained positive for the remainder of thestudy. Of the ten cats in this treatment group only one
(10%) met the criteria for persistent antigenaemia.
In treatment group T08 (Versifel FeLV) one cat died
on study days 457 and another was euthanased on study
day 91; neither of these was related to FeLV disease. Of
the remaining 14 cats none were positive for FeLV p27
antigen on study day 1164, three weeks after challenge,
and all remained negative until the end of the study.
Overall none of the cats in this treatment group met the
criteria for persistent p27 antigenaemia and conse-
quently all 14 animals (100%) were considered to be
treatment successes.
In the kitten control group T09 (no treatment), all six
kittens were positive for FeLV p27 antigen on study day
1164, three weeks after challenge, and four remained
positive on all sampling points until the end of the study.
Two kittens were negative on study day 1248 only. Con-
sequently, all six cats in this treatment group (100%)
met the criteria for persistent antigenaemia thus validat-
ing the challenge phase of the study.Gp70 Antibody and anti-FOCMA serology
Summaries of the gp70 antibody titres and the geometric
means are shown in Tables 4 and 5.20 Month challenge
Ten of 11 cats in group T04 had gp70 antibody titres of
≤30 on day −1, 42 and 617. One cat had a gp70 titre of
Table 8 Number and percentage if animals positive for FeLV pp27 antigen, and with persistent antigenaemia,
36 month DOI
Study Day T07 (water) T08 (Versifel FeLV) T09 (no treatment)
Number of animals Number (%) Number of animals Number (%) Number of animals Number (%)
−1 11 0 (0.0) 16 0 (0.0) n/a n/a
100 11 0 (0.0) 15 0 (0.0) n/a n/a
982 10 0 (0.0) 14 0 (0.0) n/a n/a
1052 10 0 (0.0) 14 0 (0.0) n/a n/a
1136 10 0 (0.0) 14 0 (0.0) 6 6 (100.0)
1164 10 1 (10.0) 14 0 (0.0) 6 6 (100.0)
1171 10 1 (10.0) 14 0 (0.0) 6 6 (100.0)
1178 10 1 (10.0) 14 0 (0.0) 6 6 (100.0)
1185 10 1 (10.0) 14 0 (0.0) 6 6 (100.0)
1192 10 0 (0.0) 14 0 (0.0) 6 6 (100.0)
1199 10 1 (10.0) 14 0 (0.0) 6 6 (100.0)
1206 10 1 (10.0) 14 0 (0.0) 6 6 (100.0)
1213 10 1 (10.0) 14 0 (0.0) 6 6 (100.0)
1220 10 1 (10.0) 14 0 (0.0) 6 6 (100.0)
1227 10 1 (10.0) 14 0 (0.0) 6 6 (100.0)
1234 10 1 (10.0) 14 0 (0.0) 6 6 (100.0)
1241 10 1 (10.0) 14 0 (0.0) 6 6 (100.0)
1248 10 1 (10.0) 14 0 (0.0) 6 4 (66.7)
Number and percentage of animals with persistent antigenaemia
10 1 (10.0) 14 0 (0.0) 6 6 (100.0)
Table 7 Number and percentage if animals positive for FeLV p27 antigen, and with persistent antigenaemia,
20 month DOI
Study Day T04 (water) T05 (Versifel FeLV) T06 (no treatment)
Number of animals Number (%) Number of animals Number (%) Number of animals Number (%)
−1 11 0 (0.0) 16 0 (0.0) n/a n/a
617 11 0 (0.0) 15 0 (0.0) n/a n/a
629 n/a n/a n/a n/a 6 0 (0.0)
652 11 6 (54.5) 15 2 (13.3) 6 6 (100.0)
659 11 6 (54.5) 15 2 (13.3) 6 6 (100.0)
666 11 5 (45.5) 15 0 (0.0) 6 6 (100.0)
673 11 3 (27.3) 15 0 (0.0) 6 6 (100.0)
680 11 3 (27.3) 15 0 (0.0) 6 6 (100.0)
687 11 3 (27.3) 15 0 (0.0) 6 6 (100.0)
694 11 3 (27.3) 15 0 (0.0) 6 6 (100.0)
701 11 3 (27.3) 15 0 (0.0) 6 6 (100.0)
708 11 3 (27.3) 15 0 (0.0) 6 6 (100.0)
715 11 3 (27.3) 15 0 (0.0) 6 6 (100.0)
722 11 3 (27.3) 15 0 (0.0) 6 6 (100.0)
729 11 3 (27.3) 15 0 (0.0) 6 6 (100.0)
736 11 3 (27.3) 15 0 (0.0) 6 6 (100.0)
Number and percentage of animals with persistent antigenaemia
11 5 (45.5) 15 0 (0.0) 6 6 (100.0)
Wilson et al. BMC Veterinary Research 2012, 8:125 Page 6 of 9
http://www.biomedcentral.com/1746-6148/8/125
Wilson et al. BMC Veterinary Research 2012, 8:125 Page 7 of 9
http://www.biomedcentral.com/1746-6148/8/125270 on day 617, prior to challenge of day 633 although
this is considered to be anomalous as it was negative for
FeLV antigen at the same sampling time point.
All of the cats in group T05 were seronegative on day
−1, but by day 42 three of 16 (19%) had antibody titres
>90 and were considered seropositive, with a group geo-
metric mean of 42.3. Two of these cats had antibody
titres that returned to <90 by day 617, while the third
had a titre if 270/90. Two cats which were negative on
day −1 and 42, had titres >90 on day 617, possibly indi-
cating a slowly developing antibody response.
All six cats in group T06 were seronegative on day
629, with gp70 antibody titres <30.
36 Month challenge
All 11 cats in group T07 had gp70 antibody titres ≤30
on study days −1, 42 and 100, although one cat at the
latter time point had a titre of <30/90. Nine cats, of the
10 remaining, had gp70 antibody titres ≤30 on study day
982 with one cat having a titre of 90 and eight cats hav-
ing titres ≤30 on study day 1052 with one cat having a
titre of 90 and another a titre of <30/90. Five cats had a
gp70 antibody titre ≤30 on study day 1136 with one cat
having a titre of 30/90, two cats having a titre of 90 and
two cats having a titre of 270.
All of the 16 cats in group T08 were seronegative on
study day −1 (gp70 antibody titres ≤30). By study day 42
(three weeks post completion of the primary vaccination
course) three of the 16 cats (19%) had gp70 antibody
titres >90 and were therefore considered to be seroposi-
tive, with a group geometric mean of 33.3. By study day
100 two of the remaining 15 cats (13%) had gp70 anti-
body titres >90, with a group geometric mean of 20.1.
On study day 982 three of the remaining 14 cats (21%)
had a gp70 antibody titre >90, with a group geometric
mean of 22.8. On study day 1052 two of the 14 cats
(14%) had gp70 antibody titres >90, with a group geo-
metric mean of 19.5. On study day 1136 two of the 14
cats (14%) had gp70 antibody titres >90, with a group
geometric mean of 26.7.
All six cats in group T09 were seronegative on study
day 1136, with gp70 antibody titres ≤30.
Bodyweights
Although there was some variation in the body weights
of cats, descriptive data summaries showed little appar-
ent difference within each individual study between
adult control and vaccinated cats over the measured
period around vaccination and the period associated
with FeLV challenge.Rectal temperatures
Descriptive data summaries showed little apparent dif-
ference within each individual study between adultcontrol and vaccinated cats in rectal temperature over
the measured period around vaccination and the period
associated with FeLV challenge.
Discussion
These studies, which were conducted according to the
requirements defined in European Pharmacopeia 5.0,
Monograph 01/2005:1321 regarding Feline Leukaemia
Vaccine (Inactivated), evaluated protection against a
FeLV challenge provided by Versifel FeLV over an
extended period. Animals were slightly younger than the
target age when first vaccinated with Versifel FeLV (be-
tween seven and eight weeks of age) and were chal-
lenged with virulent FeLV either eight months,
20 months or 36 months after the vaccination course.
Thus, at the time of FeLV challenge, cats in the adult
groups were aged approximately 10 months, 22 months
or 38 months old, while the kitten groups were approxi-
mately three to four months old. The monograph speci-
fies that for a successful challenge study, the challenge
virus must be an epidemiologically relevant isolate, and
that less than 20% of vaccinated cats should develop per-
sistent infection and more than 80% of control cats must
develop persistent infection.
When referring to the monograph requirements none
of the three studies was a complete success, even though
they all used the same vaccine. The vaccinated groups
did not show persistent antigenaemia and thus it could
be considered that the vaccine offered full protection
against a subsequent challenge with virulent FeLV dur-
ing the timescale of each study. This observation is offset
by the fact that the adult control animals in each study
did not succumb to the challenge infection in sufficient
numbers with a maximum of 45.5% animals in the
20 month duration study showing persistent antigenae-
mia. Given that the FeLV challenge was administered to
these cats when they were approximately 10 to
39 months of age, it is likely that some degree of age
related immunity to FeLV infection may have been a fac-
tor in this low rate of persistent p27 antigenaemia in un-
vaccinated cats. Age related resistance to FeLV challenge
has been reported previously [4,6] and consequently this
result was not unexpected. Indeed, one study by Hoover
and others [10] showed a rapid decrease in susceptibility
to experimental infection with FeLV, with 100% of new-
born kittens able to be infected compared to 15% of cats
aged 4 months or 1 year old. A recent study comparing
FeLV vaccine efficacy challenged cats with a considerably
smaller dose volume and titre and achieved persistent
antigenaemia in seven of eight controls, as well as five of
eight vaccinated cats at seven months of age [11]. The
high rate of p27 antigenaemia observed in the additional
kitten control groups, which were approximately 12 to
16 weeks of age when subjected to the same FeLV
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vides evidence that the chosen dose and route of admin-
istration for the FeLV material resulted in an effective
and aggressive challenge.
The anomalous gp70 antibody result seen in two cats in
treatment group T07 on study day 1136 may raise the
question of whether the cats might have been exposed to
extraneous FeLV during the post vaccination period. This
is considered to be extremely unlikely as these observa-
tions were only made in a minority of the cats and similar
results were observed in group T08 (two vaccinates which
had until day 1136 either remained seronegative or had
been seropositive on just one occasion post vaccination).
Furthermore, all cats in groups T07 and T08 remained
healthy throughout the pre-challenge period and were
confirmed to be negative for p27 antigen when tested at
various intervals prior to challenge. The cats were
obtained from a Specified Pathogen Free (SPF) facility and
were housed in a bio-security category 2 facility through-
out the duration of the study; it would therefore be ex-
tremely unlikely that extraneous FeLV virus could have
gained access into the facility.
Products of the viral envelope gene, and specifically the
major envelope protein gp70, are thought to be involved
in virus host range recognition functions, and as such are
also major targets for antibody-mediated virus neutralisa-
tion [12]. However, antibodies against gp70 are generally
not induced following vaccination [7], an observation
which appears to correlate with findings seen in this study.
This suggests that beside antibody seroconversion add-
itional immunological factors (such as cell-mediated im-
munity) should be considered in the vaccine-induced
duration of immunity against FeLV. Indeed, other studies
have shown a role for cell-mediated immunity in protec-
tion against FeLV. Flynn and others [13] showed that fol-
lowing vaccination of cats with a FeLV DNA vaccine
containing the gag/pol and env genes from the FeLV Glas-
gow A strain there was a higher level of virus-specific ef-
fector cytotoxic T lymphocytes in the peripheral blood
and lymphoid organs than observed in unvaccinated con-
trol, persistently viraemic cats. The apparent absence of
viraemia in cats following vaccination with the Versifel
FeLV vaccine, in that FeLV antigen could not be detected
in serum samples following challenge, does not mean that
infection was prevented as clinical observations showed
enlarged lymph nodes indicative of FeLV-related disease.
Other studies have shown that during an asymptomatic
phase of infection that no severe clinical signs were
observed, with some cats showing mild stomatitis or gin-
givitis, diarrhoea and mild weight loss [14], which is simi-
lar to what was observed in the current study. The
correlation of protection with low level virus neutralising
gp70 antibodies only seen in a small number of vaccinated
cats is an observation which has been reported previously.A recent study [11] examined the immunity to FeLV
induced by vaccination with a variety of inactivated
viruses. Two of the vaccines were found to protect against
subsequent challenge, but this effective containment of
the virus occurred despite minimal detectable virus neu-
tralising antibodies being seen.
Conclusion
In conclusion, we have shown that although age-related
resistance to infection with a virulent FeLV challenge is
evident from as early as 10 months of age, vaccination
with Versifel FeLV can help protect cats from FeLV
related disease up to three years after primary vaccin-
ation as kittens.
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